lasofoxifene Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy, and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.   Wikipedia

Chemistry

  • SMILES: Oc1ccc2[C@H]([C@H](CCc2c1)c3ccccc3)c4ccc(OCCN5CCCC5)cc4
  • InChIKey: GXESHMAMLJKROZ-IAPPQJPRSA-N
  • Mol. Mass: 413.56
  • ALogP: 5.73
  • ChEMBL Molecule:
    lasofoxifene  
More Chemistry

Pharmacology

Alternative names

cis-1r-(4'-pyrrolidinoethoxyphenyl)-2s-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt | (-)-cis-5,6,7,8-tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol | cp 336156 | cp-336156 | cp-336,156 | fablyn | las estrogen receptor modulator | lasofoxifene | lasofoxifene hydrochloride | lasofoxifene tartrate

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Alveolar Bone Loss (Phase 2)

Breast Neoplasms (Phase 3)

Osteoporosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue